



Brian Steingo, MD ❖ Barry Cutler, MD ❖ Ramesh Gopaldaswamy, MD ❖ Carlos Azaret, MD

CLINICAL COORDINATORS: Michele Fistel, LPN, CCRC ❖ Magdeli Ramos, CCRC ❖ Fanny Gully, CRC

CURRENTLY ENROLLING CLINICAL TRIALS - SUNRISE NEUROLOGY

Genentech-CHORDS: Relapsing Remitting MS— An open-label study to evaluate the effectiveness and safety of Ocrelizumab over a treatment period of 96 weeks (4 doses) in patients who have had a suboptimal response to an adequate course of disease modifying therapy.

MedDay-BIOTIN: Primary Progressive MS or Secondary Progressive MS—A 27 month study to evaluate the effectiveness of MD1003 VS Placebo.

Novartis-COMBI: Relapsing Remitting MS or Secondary Progressive MS—A 2 year study to evaluate the safety and efficacy of Ofatumumab VS Teriflunomide.

Sun Pharma-SPASTICITY: Spasticity Due to MS — A 22-week study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to multiple sclerosis and must be on 30-60 mg of Baclofen a day to be eligible. A long term safety study is available to those patients that complete this study.

Mallinckrodt-STAR: Relapsing Remitting MS— A 24 month observational study to gather information on recovery, treatment patterns and safety from Patients who are prescribed Acthar Gel for the treatment of relapses.

Sanofi/Genzyme-IVSS: Relapsing Remitting MS— A 7-15 day observational study to gather safety information from patients who are treated with Lemtrada.

3537 North Pine Island Road ❖ Sunrise, Florida 33351
Phone: (954)475-8171 Ext 134 Fax: (954)738-1682

■ www.infinityclinicalresearch.com